Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON

Fig. 4

Percentage of participants who achieved each lipid treatment goal with evolocumab vs placebo on background statin therapy. Values shown are means of weeks 10 and 12 except for ApoB, which was measured at week 12. The treatment differences between evolocumab and placebo for all endpoints are statistically significant at P < 0.0001 based on Cochran-Mantel–Haenszel tests stratified by study. When the calculated LDL-C was < 1.0 mmol/L or TGs were > 4.5 mmol/L, calculated LDL-C was replaced with ultracentrifugation to inform LDL-C and VLDL-C from the same blood sample, if available. ApoB apolipoprotein B, BL baseline, LDL-C low-density lipoprotein cholesterol, non-HDL-C non-high-density lipoprotein cholesterol, Q2W every 2 weeks, QM monthly, TGs triglycerides

Back to article page